In short
OV329, also known as (3S)-3-amino-4-(difluoromethylidene)cyclopentene-1-carboxylic acid hydrochloride, is an investigational substance being studied for epilepsy. Two authorised Phase 2 trials are listed, one in 12 participants with epilepsy and photosensitivity, and one in 41 adults with drug-resistant focal epilepsy. Both trials are placebo-controlled and use oral dosing.
Key points
- OV329 is an investigational antiseizure substance studied in epilepsy.
- Two authorised Phase 2 trials are registered, with 12 and 41 participants.
- One trial measures the effect on photosensitivity response in epilepsy.
- The other trial assesses safety and tolerability in drug-resistant focal epilepsy.
- Both trials compare OV329 with placebo and use oral dosing.
- No marketing authorisation for OV329 is reported in these records.
What is OV329?
OV329, whose full chemical name is (3S)-3-amino-4-(difluoromethylidene)cyclopentene-1-carboxylic acid hydrochloride, is an investigational substance being developed for epilepsy. In the registry records it appears only under the development code OV329, with no trade name or other name listed. The substance is a chemically synthesised small molecule, and no marketing authorisation is recorded, meaning it is not yet an approved medicine.
The two registered trials both list OV329 as the test substance, meaning the substance under investigation. No comparator or auxiliary role is recorded for OV329 in these trials.
How does OV329 work?
The registry data do not state a molecular target or mechanism of action for OV329. What the trials measure is a pharmacodynamic effect: the change in the standardized photosensitivity range (SPR), a measure of how sensitive a person with epilepsy is to flashing lights. The first trial evaluates this effect after single oral dosing and after repeated dosing in participants with epilepsy and a photosensitivity response. The second trial focuses on safety and tolerability in drug-resistant focal epilepsy, without describing a specific molecular mechanism.
Which conditions is OV329 studied for?
- Epilepsy with photosensitivity response — a form of epilepsy in which flashing lights can trigger abnormal brain activity, studied in a trial of 12 participants.
- Drug-resistant focal epilepsy — focal epilepsy that has not responded adequately to existing antiseizure medicines, studied in a trial of 41 adults.
How is OV329 given?
OV329 is given by mouth as an oral formulation in both registered trials. The registry records list the dose as 0 mg, which means the exact dose was not reported in the register and should not be read as the actual dose used. The trials compare OV329 with a placebo that is identical in appearance but contains no active substance.
What do the clinical trials show?
Two Phase 2 trials of OV329 are registered, both authorised and interventional. The first trial, in 12 participants with epilepsy and a photosensitivity response, measures the change from baseline in the standardized photosensitivity range on Day 1 after placebo compared with post-dose OV329 on several days. Its stated purpose is to evaluate the pharmacodynamic effect of OV329 on the photosensitivity response after single oral dosing and after repeated dosing.
The second trial, in 41 adults with drug-resistant focal epilepsy, is a double-blind, placebo-controlled study of OV329 added to existing treatment. Its primary outcomes are the incidence, severity and time course of treatment-emergent adverse events, clinically significant abnormalities in vital signs, electrocardiograms, laboratory tests and physical examinations, and treatment-emergent suicidal ideation or behaviour assessed with the Columbia Suicide Severity Rating Scale.
What side effects are known?
The registry records do not report side effects for OV329. The second trial is designed to measure safety and tolerability, including treatment-emergent adverse events and changes in vital signs, electrocardiograms and laboratory values, but no results are reported in these records.